Evidence map›Paper›PMID 25797830›Full record

ArticleNeuroImage2015

Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease.

Prashanthi Vemuri, Matthew L Senjem, Jeffrey L Gunter, Emily S Lundt, Nirubol Tosakulwong, Stephen D Weigand, Bret J Borowski, Matt A Bernstein, Samantha M Zuk, Val J Lowe and 7 more

Open access · greenAbstract read
In one paragraph

Article in NeuroImage, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Tau PET overlap index correlation with neuropathological findings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Implementation and validation of face de-identification (de-facing) in ADNI4.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  4. Article
  5. Reproducibility evaluation of the effects of MRI defacing on brain segmentation.Journal of medical imaging (Bellingham, Wash.) · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. The Overlap Index as a Means of Evaluating Early Tau PET Signal Reliability.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  10. Article
  11. Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Prashanthi VemuriDepartments of Radiology, MN, USA. Electronic address: vemuri.prashanthi@mayo.edu.
Matthew L SenjemDepartments of Radiology, MN, USA; Information Technology, MN, USA.
Jeffrey L GunterDepartments of Radiology, MN, USA; Information Technology, MN, USA.
Emily S LundtHealth Sciences Research, MN, USA.
Nirubol TosakulwongHealth Sciences Research, MN, USA.
Stephen D WeigandHealth Sciences Research, MN, USA.
Bret J BorowskiDepartments of Radiology, MN, USA.
Matt A BernsteinDepartments of Radiology, MN, USA.
Samantha M ZukDepartments of Radiology, MN, USA.
Val J LoweDepartments of Radiology, MN, USA.
David S KnopmanNeurology Mayo Clinic Rochester, MN, USA.
Ronald C PetersenNeurology Mayo Clinic Rochester, MN, USA.
Nick C FoxDementia Research Center, UCL Institute of Neurology, London, UK.
Paul M ThompsonImaging genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, University of Southern California, Los Angeles, CA, USA; Department of Psychiatry, University of Southern California, Los Angeles, CA, USA; Department of Radiology, University of Southern California, Los Angeles, CA, USA; Department of Pediatrics, University of Southern California, Los Angeles, CA, USA; Department of Engineering, University of Southern California, Los Angeles, CA, USA; Department of Opthalmology , University of Southern California, Los Angeles, CA, USA.
Michael W WeinerUniversity of California at San Francisco, Department of Veterans Affairs Medical Center, San Francisco, CA, USA; Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA.
Clifford R JackDepartments of Radiology, MN, USA.
Alzheimer's Disease Neuroimaging Initiative
Minnesota Gastroenterology · USMayo Clinic in Arizona · USSan Francisco VA Medical Center · USUniversity College London · GBUniversity of Southern California · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Amyloid Imaging, VMCI, and Analysis for ADNIRC2AG036535 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WEINER, MICHAEL W · 2009 to 2010
$23.8M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,C06RR018898 · NCRR · MAYO CLINIC · PI BURNETT, JOHN C · 2004 to 2004
$2.3M
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGYR00AG037573 · NIA · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2013 to 2015
$740k
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGYK99AG037573 · NIA · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2011 to 2012
$178k
Canadian Institutes of Health ResearchNCRR NIH HHS C06 RR018898NIA NIH HHS K99 AG037573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG16574NIA NIH HHS P50 AG16574/P1NIA NIH HHS R00 AG037573NIA NIH HHS R00 AG37573NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG040060NIA NIH HHS R01 AG11378NIA NIH HHS RC2 AG036535NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG06786
6 · The paper itself

Abstract

objectiveOur primary objective was to compare the performance of unaccelerated vs. accelerated structural MRI for measuring disease progression using serial scans in Alzheimer's disease (AD).

methodsWe identified cognitively normal (CN), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) and AD subjects from all available Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects with usable pairs of accelerated and unaccelerated scans. There were a total of 696 subjects with baseline and 3 month scans, 628 subjects with baseline and 6 month scans and 464 subjects with baseline and 12 month scans available. We employed the Symmetric Diffeomorphic Image Normalization method (SyN) for normalization of the serial scans to obtain tensor based morphometry (TBM) maps which indicate the structural changes between pairs of scans. We computed a TBM-SyN summary score of annualized structural changes over 31 regions of interest (ROIs) that are characteristically affected in AD. TBM-SyN scores were computed using accelerated and unaccelerated scan pairs and compared in terms of agreement, group-wise discrimination, and sample size estimates for a hypothetical therapeutic trial.

resultsWe observed a number of systematic differences between TBM-SyN scores computed from accelerated and unaccelerated pairs of scans. TBM-SyN scores computed from accelerated scans tended to have overall higher estimated values than those from unaccelerated scans. However, the performance of accelerated scans was comparable to unaccelerated scans in terms of discrimination between clinical groups and sample sizes required in each clinical group for a therapeutic trial. We also found that the quality of both accelerated vs. unaccelerated scans were similar.

conclusionsAccelerated scanning protocols reduce scan time considerably. Their group-wise discrimination and sample size estimates were comparable to those obtained with unaccelerated scans. The two protocols did not produce interchangeable TBM-SyN estimates, so it is arguably important to use either accelerated pairs of scans or unaccelerated pairs of scans throughout the study duration.

Indexed as

AgedAged, 80 and overAlgorithmsAlzheimer DiseaseArtificial IntelligenceBrain MappingCognitive DysfunctionDatasets as TopicDiffusion Tensor ImagingDisease ProgressionFemaleHumansImage Processing, Computer-AssistedMaleMiddle AgedNeuroimaging

Identifiers

PMID25797830
PMCPMC4456670
OpenAlexW1995386242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.